Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wiemer

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
European Journal of Heart Failure|December 14, 2019
Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18Martin Möckel, Rudolf A de Boer, Anna Christine Slagman, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 28, 2022
In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibitionAnne-Rose W Schut, Anne L M Vriends, Andrea Sacchetti, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2010
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis studyInge R H M Konings, Stefan Sleijfer, Ron H J Mathijssen, et al.
Clinical Pharmacology and Therapeutics|November 23, 2006
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patientsBronno van der Holt, Marry M Van den Heuvel-Eibrink, Ron H N Van Schaik, et al.
Molecular Pharmacology|June 26, 2015
Lysosomal Sequestration Determines Intracellular Imatinib LevelsHerman Burger, Alexander T den Dekker, Sandra Segeletz, et al.
British Journal of Clinical Pharmacology|June 30, 2015
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanesAnne-Joy M de Graan, Alex Sparreboom, Peter de Bruijn, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2013
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancerR J van Soest, M E van Royen, E S de Morrée, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2014
Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumorsDiane A J van der Biessen, Herman Burger, Peter de Bruijn, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 8, 2010
Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometryWalter J Loos, Anne-Joy M de Graan, Peter de Bruijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumorsFerry A L M Eskens, Francisco J Ramos, Herman Burger, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
European Journal of Heart Failure|December 14, 2019
Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18Martin Möckel, Rudolf A de Boer, Anna Christine Slagman, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 28, 2022
In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibitionAnne-Rose W Schut, Anne L M Vriends, Andrea Sacchetti, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2010
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis studyInge R H M Konings, Stefan Sleijfer, Ron H J Mathijssen, et al.
Clinical Pharmacology and Therapeutics|November 23, 2006
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patientsBronno van der Holt, Marry M Van den Heuvel-Eibrink, Ron H N Van Schaik, et al.
Molecular Pharmacology|June 26, 2015
Lysosomal Sequestration Determines Intracellular Imatinib LevelsHerman Burger, Alexander T den Dekker, Sandra Segeletz, et al.
British Journal of Clinical Pharmacology|June 30, 2015
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanesAnne-Joy M de Graan, Alex Sparreboom, Peter de Bruijn, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2013
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancerR J van Soest, M E van Royen, E S de Morrée, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2014
Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumorsDiane A J van der Biessen, Herman Burger, Peter de Bruijn, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 8, 2010
Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometryWalter J Loos, Anne-Joy M de Graan, Peter de Bruijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumorsFerry A L M Eskens, Francisco J Ramos, Herman Burger, et al.
Pageof 13